Oxytocin 10mg (6000 IU)

Oxytocin has been validated in nearly 25,000 peer-reviewed publications spanning nine decades:

• Receptor Structural Biology: Meyerowitz et al. (2022) solved cryo-EM structure of OXTR-Gq signaling complex at high resolution, identifying magnesium coordination complex essential for oxytocin-receptor binding and discovering single amino acid position acting as molecular switch for cation dependence across vasopressin receptor family
• Social Behavior and Neural Circuits: Rigney et al. (2022, Endocrinology) mapped neural circuits in paraventricular nucleus, supraoptic nuclei, bed nucleus of stria terminalis mediating maternal nurturing, social reward, pair bonding, social recognition. Optogenetic and chemogenetic manipulation studies demonstrated oxytocin-dopamine crosstalk in ventral tegmental area and nucleus accumbens. Fiber photometry recording captured oxytocin release dynamics during social interactions
• Neuromodulation and Plasticity: Froemke & Young (2021) demonstrated oxytocin facilitates long-term synaptic plasticity through experience-dependent neural reorganization, including disinhibition in auditory cortex during maternal behavior learning in rodents. Established oxytocin as attentional modulator increasing salience of social information through three-tiered neuromodulatory action
• Stress Axis Modulation: Althammer et al. (2021) documented parvocellular oxytocin neurons function as "master cells" regulating entire oxytocin system. Oxytocin administration inhibits CRF mRNA expression at hypothalamus, reduces ACTH and cortisol in multiple stress paradigms (restraint, social defeat, predator exposure)
• Metabolic Effects: Ding et al. (2019) reviewed multi-pronged metabolic actions: promotes lipolysis and beta-oxidation in adipose tissue, reduces macrophage infiltration, improves beta-cell responsivity and glucose tolerance. Snider et al. (2019) demonstrated long-acting selective OXTR agonists show antidiabetic and antiobesity effects in male mice with dose-dependent reductions in body weight, improved glucose tolerance, and enhanced insulin sensitivity
• Cardiovascular Protection: Jankowski et al. (2020) documented ischemia-reperfusion injury protection through PI3K/Akt/RISK pathway activation in multiple cardiac injury models. Wasserman et al. (2022) showed oxytocin promotes epicardial cell activation and heart regeneration after cardiac injury. Demonstrated NLRP3 inflammasome inhibition, IL-1β and TNF-α suppression, nitric oxide release, and atrial natriuretic peptide-mediated protection
• Bone and Musculoskeletal: Breuil et al. (2021) reviewed anabolic effects on bone: promotes osteoblast differentiation via BMP-2 upregulation and estrogen-dependent pathways, dual effects on osteoclasts (promotes differentiation but inhibits resorptive capacity). Bone mineral density correlations with endogenous oxytocin levels in postmenopausal women. Prevents age-related sarcopenia in oxytocin knockout animal models
• Clinical Safety (Meta-analyses): MacDonald et al. (2011) reviewed 38 RCTs with 1,529 participants: intranasal oxytocin (18-40 IU) "produces no detectable subjective changes" and "produces no reliable side-effects." Cai et al. (2018) meta-analysis of 5 RCTs with 223 ASD participants found no statistically significant difference in adverse event rates between oxytocin and placebo. Most common: nasal discomfort (14.3%), irritability (9.0%), tiredness (7.2%)
• Clinical Efficacy (ASD): Zhang et al. (2025) meta-analysis of 12 RCTs with 498 ASD patients (252 oxytocin, 246 placebo): no significant overall effect at standard doses, but at 48 IU/day, beneficial effects on social impairments emerged. Dose-response analysis indicated higher doses more effective for both social impairments and repetitive behaviors. Sikich et al. (2021, NEJM, SOARS-B trial) 290 children/adolescents: no significant overall between-group differences, but subsequent biomarker analyses identified low baseline OXT subpopulations showing greater improvement

Pharmacokinetics: Quintana et al. (2021) reported intranasal bioavailability ~0.7-2%, with direct nose-to-brain transport accounting for >95% of brain-detected oxytocin. Plasma half-life 3-5 minutes for IV administration; intranasal brain concentrations peak at 30-60 minutes, return to baseline 90-120 minutes.